SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-036224
Filing Date
2024-02-14
Accepted
2024-02-14 16:14:58
Documents
14
Period of Report
2024-02-14
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d771919d8k.htm   iXBRL 8-K 21983
  Complete submission text file 0001193125-24-036224.txt   143324

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kalv-20240214.xsd EX-101.SCH 2853
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20240214_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20240214_pre.xml EX-101.PRE 11263
15 EXTRACTED XBRL INSTANCE DOCUMENT d771919d8k_htm.xml XML 3648
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 24638354
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)